Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae

  • Gómara-Lomero, Marta
  • López-Calleja, Ana Isabel
  • Rezusta, Antonio
  • Aínsa, José Antonio
  • Ramón-García, Santiago
Treatment of infections caused by multi-drug resistant (MDR) enterobacteria remains challenging due to the limited therapeutic options available. Drug repurposing could accelerate the development of new urgently needed successful interventions. This work aimed to identify and characterise novel drug combinations against Klebsiella pneumoniae based on the concepts of synergy and drug repurposing. We first performed a semi-qualitative high-throughput synergy screen (sHTSS) with tigecycline, colistin and fosfomycin (last-line antibiotics against MDR Enterobacteriaceae) against a FDA-library containing 1430 clinically approved drugs; a total of 109 compounds potentiated any of the last-line antibiotics. Selected hits were further validated by secondary checkerboard (CBA) and time-kill (TKA) assays, obtaining 15.09% and 65.85% confirmation rates, respectively. Accordingly, TKA were used for synergy classification based on determination of bactericidal activities at 8, 24 and 48 h, selecting 27 combinations against K. pneumoniae. Among them, zidovudine or azithromycin combinations with last-line antibiotics were further evaluated by TKA against a panel of 12 MDR/XDR K. pneumoniae strains, and their activities confronted with those clinical combinations currently used for MDR enterobacteria treatment; these combinations showed better bactericidal activities than usual treatments without added cytotoxicity. Our studies show that sHTSS paired to TKA are powerful tools for the identification and characterisation of novel synergistic drug combinations against K. pneumoniae. Further pre-clinical studies might support the translational potential of zidovudine- and azithromycin-based combinations for the treatment of these infections.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Transcriptomic profile of the most successful Mycobacterium tuberculosis strain in Aragon, the MtZ strain, during exponential and stationary growth phases

  • Comín, Jessica
  • Campos, Elena
  • Gonzalo-Asensio, Jesús
  • Samper, Sofía
The Mycobacterium tuberculosis Zaragoza (MtZ) strain has produced the largest outbreak in Aragon Community, Spain, as it started in the 90s and continues today, contributing with more than 240 cases of tuberculosis, around 10% of the TB cases. Previous studies were carried out to identify the reasons for its successful spread capacity among the population. Some single nucleotide polymorphisms (SNPs) in genes considered as virulence factors were found, as well as an oversecretion of PE_PGRS factors. Different copies of IS6110 have been localized, and a transcriptomic study was carried out to study how the different IS6110 copies could affect the adjacent gene expression. In this work, we analyzed the transcriptomic profile of the MtZ, strain trying to delve into the mechanisms behind its success. We found that ESX-1 system is upregulated during both exponential and stationary growth phases in vitro, as well as the virulence pathways of cholesterol degradation and peptidoglycan biosynthesis. In addition, MtZ has the iron uptake genes downregulated in exponential growth phase (mycobactin biosynthesis and IrtAB transporters), while the iron storage could be upregulated. The desA3 gene transcription was interrupted by the insertion of an IS6110 copy. This gene codes for a stearoyl-coenzyme A (CoA) Δ9 desaturase involved in the production of oleic acid, which is necessary for the metabolism of the bacteria. In spite of this, although MtZ strain has an initial long lag phase growing in liquid media, it is capable of achieving normal growth, suggesting the existence of an alternative route for obtaining oleic acid.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Toward tuberculosis elimination: An update on tuberculosis vaccines in clinical trials

  • Martín, Carlos
  • Gonzalo-Asensio, Jesús
  • Aguiló, Nacho
  • Arbués, Ainhoa
Despite major advances in diagnosis and treatment, tuberculosis (TB) control – and ultimately elimination – will remain unachieved without a vaccine capable of preventing pulmonary disease and transmission. Bacille Calmette–Guérin (BCG), a live attenuated vaccine derived from Mycobacterium bovis and the only licensed TB vaccine, has been widely implemented because of its proven efficacy against severe childhood TB. However, despite global coverage approaching 90%, BCG provides limited and inconsistent protection against pulmonary TB in adolescents and adults, the populations that sustain transmission. In response, a diverse pipeline of novel TB vaccine candidates has emerged across multiple technological platforms. This review provides an updated overview of TB vaccines in clinical development. Currently, sixteen candidates are undergoing clinical evaluation, including four in active Phase 3 efficacy trials. This review also offers critical insights into challenges shaping late-stage TB vaccine development. We argue that evolving understanding of Mycobacterium tuberculosis infection – including heterogeneity within latent infection, the contribution of subclinical disease, and limitations of binary IGRA-based classification – necessitates reassessment of current efficacy endpoints. By examining prevention-of-disease (PoD), prevention-of-infection (PoI), and prevention-of-recurrence (PoR) strategies, we highlight the need for closer alignment between biological insight, trial design, and policy objectives to ensure that new vaccines advance TB elimination.